Combination therapy of a mouse sarcoma using razoxane and electron irradiation. by Grimshaw, M. B. et al.
Br. J. Cancer (1981) 44, 117
COMBINATION THERAPY OF A MOUSE SARCOMA USING
RAZOXANE AND ELECTRON IRRADIATION
M. BARKER GRIMSHAW*t, R. W. DAVIESt AND W. S. HALL§
Fromn the *Cancer Chemotherapy Department, Imperial Cancer Research Fund, London
WC2A 3PX; $Department ofPhysics, and §Department ofRadiobiology, Medical College of
St. Bartholomew's Hospital, London EC1M 6BQ
iRueeeiL 2() Mllarcli 1980 Aecepted 23 Alarch 1981
Summary.-The combination of a single dose of razoxane (ICRF 159) with a single
dose of electron radiation has been studied with the murine sarcoma S180. A drug
dose of30 mg/kg combined with radiation produced a greater tumour response than
either agent alone, but it was notpossible to establish whetherthe effect was more than
additive.
Direct measurements of tumour and s.c. oxygen concentrations and studies of
tumour-cell respiration were carried out after various razoxane treatments in an
attempt to elucidate mechanisms ofaction. There were no indications at the drug dose
levels used in the radiation studies of any significant changes in tissue oxygenation
or cellular respiration.
THE COMBINATION ofthe drug, razoxane
(ICRF 159 (±) 1,2-di(3,5-dioxopiperazin-
1-yl propane) and irradiation has been
uised in several recent clinical studies (e.g.
Ryall et al., 1979; Spittle et al., 1979).
The first report of an effect of the drug in
a murine system was by Hellmann &
Murkin (1974) using Sarcoma 180 and a
fractionated radiation/drug regime. Raz-
oxane alone was reported to have a "nor-
malizing" effect on the vasculature of
experimental tumours with poorly deve-
loped blood vessels (Salsbury et al., 1974).
The suggestion was madeby Hellmann and
Murkin that their observations could have
been brought about by the effect of raz-
oxane on the developing tumour neo-
vasculature, indirectly sensitizing the
hypoxic cells in the tumour.
However, preliminary studies by Barker
Grimshaw (unpublished) indicated that
some additional tumour response was
manifest when razoxane was administered
as a single dose 1 h before a single dose of
X-rays (i.e. before any gross structural
alteration in the tumour neovasculature
could have occurred).
An alternative mechanism by which
razoxane could be affecting radiation
response would be by altering the tissue
02 concentration. Miko & Chance (1974)
reported that razoxane inhibited endo-
genous respiration of Ehrlich Lettre cells
in vitro. Such inhibition, if occurring in
vivo, would allow 02 to diffuse to a greater
distance from blood capillaries and hence
oxygenate previously hypoxic (but pos-
sibly clonogenic) tumour cells. Some evi-
dence for increased tumour 02 concentra-
tion following razoxane treatment came
from the work ofNorpoth et al. (1974) and
unpublished work of the present authors.
However, in both cases the tumour used
had been given repeated doses ofrazoxane.
The work presented here set out con-
currently to investigate the effect on a
mouse sarcoma of a single razoxane treat-
ment combined with a single dose of
ionizing radiation; the effect of different
doses of razoxane on tumour and normal-
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tissue 02 concentration; and the effect of
razoxane on tumour-cell respiration.
MATERIALS AND METHODS
The murine sarcoma 180 (S180) w%Nas used
in these experiments. For tumour-response
studies, 1-month-old, male, Schneider mice
were inoculated s.c. in the flank with 107
S180 cells in 0-1 cm3 sterile mash. Ten days
after implantation, mice the tumours of
which had reached a volume of -0 5 cm3
were randomized into groups of 10 and given
the various treatments.
The drug razoxane was made up as a fine
suspension in carboxymethyl cellulose (CMC)
as described by Hellmann & Murkin (1974).
Drug concentrations were adjusted so that
mice received i.p. injections of 0-2-0-3 cm3
according to their body weight. Control
animals received i.p. injections of the appro-
priate volume of CMC.
For irradiation or measurements of tissue
02 concentration, animals were anaesthetized
with Avertin (tribromoethanol (Winthrop),
250 mg/kg) which rendered the mice comatose
for 30 min.
Tumour response.-Tumour response to the
various treatments was assessed by measuring
tumour volumes thrice weekly starting on the
treatment day (Day 10 after implantation).
Three perpendicular measurements oftumour
diameter were taken using Vernier calipers,
and the product, the '"relative tumour
volume" for each treatment group was plotted
against time from the start of treatment, to
produce a tumour growrth curve, after first
relating the mean group tumour size to the
mean size on the first day of treatment. On
Day 28 the mean tumour volume ofuntreated
animals was 5-4 + 0 3 cm3, which necessitated
their being killed. Therefore the area under
the growrth curve from Day 1i) to Day 28
(after implantation) was calculated and
related to that of the control group to obtain
a value representing tumour response to
treatment. (See also Discussion.)
This relative response is defined as
area under the tumour growth curve for
treatment group
area under the tumour growth curve for
control group
Irradiation.-Mice wAere treated w%ith a
single injection ofeither razoxane or CMC, 1 h
before irradiation, this being the interval
used by Hellmann and Murkin (1974). Three
doses of razoxane were used in the present
experiments: 6-25, 15 and 30 mg/kg. The
pretreated mice were anaesthetized with
Avertin just before irradiation and placed
singly on a Perspex platform which could be
mounted vertically behind a collimator in the
electron beam. The radiation field was defined
by an Al-Pb collimator with suitable hole to
include the tumour. Ionization chambers
were used to monitor the incident electron
beam, and calibrations carried out so that
the beam could be switched off automatically
when the required dose had been delivered to
the tumours. Lithium fluoride powder in
sachets was used to confirm the doses. Groups
of mice were given 1-5, 3 or 6 Gy of 15-4MeV
electrons from a linear accelerator at a dose
rate of 11 Gy/s. Although the total time
the mice spent in the irradiation room was
only about 2 min, they were gassed with
warmed air (28°C, flowr rate 6 1/min, ambient
temperature 24°C) to ensure that their tissues
remained normally oxygenated and to main-
tain body temperature.
Oxygen cathode measurenien,ts.-The con-
struction and use of the electrodes and the
measuring apparatus have been described
elsewhere (Davies & Hall. 1973; Shewell &
Davies, 1977; Roberts et al. (1975).
Electrodes were calibrated at the start of
every experiment in air-saturated physio-
logical saline at 37°C. Solutions containing
razoxane at concentrations up to the equiva-
lent of 1000 mg/kg in animals had no effect
on the electrodes.
Mice were treated w%iith razoxane or CMC,
1 h before tissue 02 measurements. Four
doses of razoxane were used: 15, 30, 100 and
500 mg/kg. Fifty min later 2 mice were
anaesthetized with Avertin, 1 CMC-treated
and 1 razoxane-treated. The fur over the
tumours was gently trimmed. The mice Mere
then positioned supine on a Perspex platform
and restrained with adhesive tape.
Two electrodes were placed into each
tumour and one electrode placed s.c., a
25-gauge needle being used to facilitate skin
penetration. A reference electrode was posi-
tioned in the rectum.
The platform was then placed in a poly-
thene bag with an air or 02 inlet at one end,
the other end remaining open. A lamp was
positioned above the mice to maintain body
temperature. Electrode readings were taken
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every minute until a steady state was reached
(5-10 min). 100% 02 at atmospheric pressure
was then passed through the bag at 41/min,
again until steady state was attained. After
each experiment, the depth of penetration
of each electrode was recorded and the mice
killed.
Cell respiration.-Schneider mice bearing
the S180 tumour in the ascitic form were
killed 7 days after i.p. tumour transplanta-
tion, and the ascites fluid added to ice-cold
E4 medium (Eagle's medium, Dulbecco's
modification, made up by the Central Service
Division of the ICRF). The cell suspension
was centrifuged at 800 rev/min for 10 min,
and any contaminating erythrocytes removed
by the hypertonic lysis method (Chance &
Hess, 1959). Cells w%Nere resuspended in E4
medium. Viability after such treatment -NNas
not less than 85%. The prepared cell suspen-
sion was divided amongst 4 Burler flasks each
containing 200 cm3 E4 at 37°C and the appro-
priate concentration of razoxane (0, 10, 100
and 1000 Htg/cm3) dissolved in 0-4M HCI.
Flasks w-ere rolled for 1 h at 37°C. After
exposure to razoxane, cells were collected by
centrifugation, washed and suspended in
5 cm3 ice-cold E4 medium and kept on
ice throughout 02 consumption studies. In a
further series of experiments, cells were
treated with razoxane, collected, washed and
r-esuspended in E4 medium as described
above, except that the appropriate amount of
razoxane was added to the cell suspension.
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Thus stocks of cells which had been treated
with the drug at 37°C for 1 h remained
exposed to the drug during storage on ice
before the respiration studies.
Oxygen consumption was measured with a
Clark-type electrode calibrated with 3 cm3
air-saturated physiological saline at 37°C.
About 107 S180 cells in 3 cm3 E4 were added
to the reaction vessel, and after 5min
equilibration the fall in current with time was
recorded. Usually 107 cells used up all the
available 02 in about 10 min.
RESULTS
Tumour response to treatment with razoxane,
electron radiation or both
The data for the tumour response of
groups of 10 mice treated in various ways
are shown in Fig. 1. There is a small but
increasing effect of razoxane alone for
doses of 15 mg/kg and 30 mg/kg. There is
no significant effect for the dose of 6-25
mg/kg.
Doses of 1Pa, 3 and 6 Gy of 15MeV
electrons produce a reduction in tumour
growth, as shown by values of relative
tumour response less than unity. There is
no significant difference between the
tumour responses for radiation alone and
combined with 6-25 mg/kg or 15 mg/kg
razoxane.
6. 25 15 30 1.5 3 6 6.25 mg/kg 15 mg/kg 30 mg/kg
Razoxane Electron + + + + + + +
(mg/kg) Irradiation (Gy) 1.5 3 6 3Gy 6Gy 3Gy 6Gy
Gy Gy Gy
Razoxane + Electron Irradiation
FiG. 1.-TuLmotur response to treatment witlh single or eombination (loses of razoxane and radiation.
I e
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Only when 30 mg/kg razoxane is com-
bined with 3 or 6 Gy is a significant in-
crease in tumour response observed,
though it is not possible to distinguish
whether this increased effect is merely
additive or whether there is potentiation.
Oxygen concentrations
Fig. 2 shows tumour 02 concentrations
for mice 1 h after injection with 0, 15, 30,
100 or 500 mg/kg razoxane. For the control
mice (CMC only) the 02 concentration for
air-breathing animals was 12 5 + 1*8 mM/im3
(mean of 38 readings).
No significant differences were seen for
the various doses of razoxane, except for a
depression for the 100 mg/kg dose to
6-2 + 1P0 mM/M3. Giving the animals 100%
02 to breathe might amplify any differen-
ces that exist, anddata for 02breathing are
also shown in Fig. 2. A control value of
29.9 + 6.4 mM/M3 (38 readings) was in fact
reduced considerably for 30 and 100 mg/
kg.
40
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0
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0 15 30 100 501
Razoxane (mg/kg)
Fia. 2. Tumour 02 concentrations for mice
breathlilng air (A) or 02 after v-arious doses
of razoxane.
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FI[G. 3.-Subcutaneous 02 concentrations for
mice breathing air or 02 after various (loses
of razoxane.
For s.c. tissue the data are shown in
Fig. 3. Initial air-breathing values for the
controls of 48-9 + 50 mM/M3 (21 readings)
rose to 84 7 + 10 4 mM/m3 (21 readings)
for 02 breathing. No significant differences
were observed for the various drug doses,
except for a 30-40%o depression in 02 con-
centration for 15 mg/kg drug dose.
Cell respiration
Theeffectof 1hincubationwith razoxane
(0, 10, 100, or 1000 ,ug/cm3) on the 02
consumption of S180 cells is shown in the
Table. It is apparent that razoxane for 1 h
at 37TC does not significantly influence 02
consumption. Indeed, when the experi-
ments were repeated with razoxane in-
cluded in the medium of the stock cell
suspension kept on ice, there was again no
detectable difference between oxygen
consumption for control and treated cells.
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TABLE. Oxygen consumption for 8180
cells in vitro in mnedia containiny variouts
concentrations ofrazoxane
Razoxane
(0g/cm3) 0 1() 100 1000
02 consllmptioIn
(mMT x 10-5/min/
107 cells+s.e.) 42±+02 4-0+0-2 :39+02 4-1+0-1
DISCUSSION
The Cancer Chemotherapy National
Service Centre of the National Cancer
Institute (Bethesda) expresses results of
solid-tumour chemotherapy as the ratio
(treated tumour volume or weight)/(con-
trol tumour volume or weight) at a set time
after treatment. However, there is always
the problem in such time- or size-point
determinations that the unavoidable cull-
ing of large tumours immediately before
assessment can affect results. Radio-
biologists commonly use methods such as
regrowth delay (the time to regrow after
treatment at a fixed size to a new standard
volume; Thomlinson & Craddock, 1967)
or TCD50 (the treatment dose that cures
500/o of tumours; Suit et al., 1.965). As the
above experiments were designed to
measure tumour response to small radia-
tion doses, such as commonly used in
fractionated clinical therapy, no complete
cures would be expected, and the TCD50
assay could not therefore be used. The
regrowth-delay method suffers from the
same disadvantage as the single T/C
method (Denekamp & Harris, 1975). How-
ever, this problem can be solved by
measuring the area under the tumour
growth curve between the time limits of
treatment day and final measurement day
(see Methods). This method was therefore
the one of choice and results were ex-
pressed using the T/C ratio.
The combination of 30 mg/kg razoxane
and radiation produced a greater relative
tumour response than for either agent
alone. It was not possible to establish
whether the effect was only additive with
the data available but neither 6-25 mg/kg
nor 15 mg/kg razoxane in combination
with radiation produced an effect greater
than with only one agent.
The direct measurements of tumour 02
for air-breathing animals were no different
from measurements commonly found in
experimental tumours. The results for
animals treated with drug doses within
the range used in the radiation studies
were not different from control values. At
the higher drug dose, 100 mg/kg, there is a
deviation from the control value, but this
is not apparent at the highest clrug dose
used, 500 mg/kg. Oxygen-breathing ani-
mals, given no razoxane, had a raised 02
concentration, and this was also found in
animals treated with the lowest and high-
est razoxane doses (15 and 500 mg/kg).
However, doses of 30 and 100 mg/kg
apparently reduiced the relative increase in
tumour 02 concentration when breathing
02 rather than air. This is the; reverse of
what would be expected if increased
tumour 02 concentration were to explain
the radiation result. This unexpected
dose-effect relationship may be due to the
absorption characteristics of razoxane.
Problems with the absorption of orally
administered razoxane have been noted
(Creaven et al., 1974). Ideally the concen-
tration of razoxane in mouse plasma
should be measured, but as yet no such
assay is readily available (Margaret Col-
lins, personal communication).
For the s.c. tissues, the 02 concentrationi
in air-breathing control animals is as
expected, and increases when pure 02 iS
breathed. However, treatment with the
lowest razoxane dose (15 mg/kg) reduces
the relative increase in 02 concentration
when animals change from breathing air
to pure 02. The 02 concentrations at
higher razoxane doses are in the same
range as the control values for both air-
and oxygen-breathing mice. Thus the
reduction in the relative increase in 02
concentration when breathing 02 instead
of air occurs in tumour tissue and, at
lower drug doses, in s.c. tissue. It might
be expected that the "normal" vasculature
of s.c. tissue would be more sensitive to
treatment which affects vascular function
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than tumour vasculature, which is gener-
ally considered to be poorly developed.
Indeed many studies have shown that
normal and malignant tissues react differ-
ently to various vasoactive stimuli, for
example Kruuv et al. (1967).
In conclusion, our tumour-response data
support the view of others (Taylor &
Bleehen, 1977) that razoxane-induced
changes in the developing neovasculature
are not a necessary requirement for pro-
ducing increased radiation effects.
The direct 02 cathode measurements
suggest that razoxane does not affect
tumour 02 concentration over the range
ofdrug doses used in the radiation studies.
Variations seen at higher drug doses may
be due to the absorption characteristics
of the drug. In vitro studies oftumour-cell
respiration revealed no change in 02
consumption, even at the highest drug
dose.
There is no need, therefore, for changes
in tumour 02, from whatever cause, to
explain the increased radiation response
seen with S180, and the particular treat-
ment schedule used above. A range of
tumour types and schedules needs to be
investigated before this possible mode of
action can be eliminated.
The varied biological properties of
razoxane have elicited many suggestions
as to its mode of enhancing the radiation
response. Razoxane may well enhance
radiation via a number of different mech-
anisms and the contribution of any one
of these to the final result may differ
according to the tumour and treatment
schedule used. This may well be why the
combination of razoxane with radiation
has produced conflicting results; e.g.
Peters, 1976; Sheldon & Hill, 1977;
Bakowski et al., 1978; Bates, 1978; Hell-
mann et al., 1978; Ryall et al., 1979.
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